Quality Chemical Industries Limited landed 36 million dollars from Stanbic Bank Uganda for factory expansion. The pharmaceutical company will build a second manufacturing plant at its Luzira location. This funding allows Qcil to boost production from 1.4 billion tablets yearly to 2.4 billion tablets. The new facility brings injectable medicine production and tuberculosis treatment manufacturing to Uganda. Company leaders expect the expanded capacity to serve more African countries with affordable drugs.
Qcil already leads regional production of HIV and malaria medications approved by the World Health Organization. The company, founded in 2005, sells products across 31 African nations from its Kampala headquarters. Local manufacturers currently supply just 10 percent of the antiretroviral drugs needed for 5 million HIV patients. Regional producers also provide only 19 percent of malaria treatments despite 54 million cases each year. East Africa reports over 600,000 tuberculosis cases annually, but produces no TB medicines locally.
Chairman Emmanuel Katongole said the expansion strengthens their mission to reduce medicine import dependence across Africa. Chief Executive Ajay Kumar Pal called the project a major investment for continental healthcare access. Stanbic executives Paul Muganwa and Mumba Kalifungwa praised the deal as vital for regional medical supply chains. The bank structured the loan through its Corporate and Investment Banking division. All parties expect the facility to boost local pharmaceutical manufacturing significantly.
Qcil already leads regional production of HIV and malaria medications approved by the World Health Organization. The company, founded in 2005, sells products across 31 African nations from its Kampala headquarters. Local manufacturers currently supply just 10 percent of the antiretroviral drugs needed for 5 million HIV patients. Regional producers also provide only 19 percent of malaria treatments despite 54 million cases each year. East Africa reports over 600,000 tuberculosis cases annually, but produces no TB medicines locally.
Chairman Emmanuel Katongole said the expansion strengthens their mission to reduce medicine import dependence across Africa. Chief Executive Ajay Kumar Pal called the project a major investment for continental healthcare access. Stanbic executives Paul Muganwa and Mumba Kalifungwa praised the deal as vital for regional medical supply chains. The bank structured the loan through its Corporate and Investment Banking division. All parties expect the facility to boost local pharmaceutical manufacturing significantly.
